Nivolumab for the treatment of small cell lung cancer-Reference-Cited by-同舟云学术

Nivolumab for the treatment of small cell lung cancer

Published:2019-10-29 Issue:1 Volume:14 Page:5-13
ISSN:1747-6348
Container-title:Expert Review of Respiratory Medicine
language:en
Short-container-title:Expert Review of Respiratory Medicine

Author:

Simeone Ester¹,Grimaldi Antonio Maria¹,Festino Lucia¹,Trojaniello Claudia¹,Vitale Maria Grazia¹,Vanella Vito¹,Curvietto Marcello¹,Ascierto Paolo Antonio¹^ORCID

Affiliation:

1. Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy

Publisher

Informa UK Limited

Subject

Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/17476348.2020.1681977

Reference45 articles.

1. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

2. Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.

3. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

4. Small-cell lung cancer

5. Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of Matrix Stiffness and Hepatocyte Growth Factor on Small Cell Lung Cancer Cells in Decellularized Extracellular Matrix‐Based Hydrogels;Macromolecular Bioscience;2023-10-31

2. Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort study;BMJ Open;2023-02

3. Energy performance in residential buildings: Evaluation of the potential of building design and environmental parameter;Ain Shams Engineering Journal;2022-06

4. Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer;Frontiers in Oncology;2021-03-18